Morocco authorizes three cannabis-based medicines to treat epilepsy
Published
The Moroccan pharmaceutical laboratory Sothema has recently reached an important milestone in the healthcare sector. The company has obtained marketing authorizations (MA) for three new medicines manufactured from therapeutic cannabis.
These treatments are specifically intended for patients suffering from epilepsy. This decision marks a turning point in the country's health policy, which seeks to integrate cannabis derivatives into official care protocols to improve the quality of life for patients.
The validation process was overseen by Moroccan health authorities, ensuring that these medicines meet strict safety and quality standards. The goal is to offer effective therapeutic alternatives for complex neurological conditions that sometimes resist conventional treatments.
This advancement is part of a broader context of legalization and regulation of cannabis for medical and industrial purposes in Morocco. The country aims to develop an innovative pharmaceutical industry while offering new solutions to patients.
For observers, this news is significant, as it shows an evolution in mindsets and legislation regarding the medical use of cannabis. These medicines should be available soon in Moroccan pharmacies, subject to a rigorous medical prescription.
Sources: Newsweed
More France news
- Maxime Pavageau, 29, wins France's best young wine seller title
- A New, Highly Promising Concrete
- Paris and Île-de-France: Immersive Exhibitions to Experience Art Differently
- France 3 broadcasts a documentary on the history of the Téléthon, narrated by Zazie
- ChatGPT launches business profiles with mention and click statistics
- Trail: France Outdoor Seeks to Frame Environmental Restrictions
- A Roanne company bets on knitwear made in France
- Sport: Major Win for the Brûleurs de Loups and Six Internationals Absent for FC Annecy